IL-12 gene therapy for cancer: in synergy with other immunotherapies

In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) h as reached unprecedented levels of success when combined with immunotherapy approaches such its gene transfer of other cytokines and/or chemokines. co stimulatory molecules or adoptive cell therapy. These combinations have bee n found to produce synergistic rather than additive effects. Meanwhile, IL- 12 gene therapy is beginning clinical testing as a single agent, but combin ation strategies are at hand.